Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.31
SPPI's Cash to Debt is ranked higher than
60% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 68.42 vs. SPPI: 1.31 )
SPPI' s 10-Year Cash to Debt Range
Min: 0.2   Max: 17918
Current: 1.31

0.2
17918
Equity to Asset 0.56
SPPI's Equity to Asset is ranked higher than
66% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. SPPI: 0.56 )
SPPI' s 10-Year Equity to Asset Range
Min: 0.2   Max: 0.95
Current: 0.56

0.2
0.95
F-Score: 3
Z-Score: 0.98
M-Score: -2.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 29.82
SPPI's Operating margin (%) is ranked higher than
76% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -68.50 vs. SPPI: 29.82 )
SPPI' s 10-Year Operating margin (%) Range
Min: -68658.54   Max: 29.82
Current: 29.82

-68658.54
29.82
Net-margin (%) 35.32
SPPI's Net-margin (%) is ranked higher than
73% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. SPPI: 35.32 )
SPPI' s 10-Year Net-margin (%) Range
Min: -67890.24   Max: 35.32
Current: 35.32

-67890.24
35.32
ROE (%) 33.19
SPPI's ROE (%) is ranked higher than
71% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. SPPI: 33.19 )
SPPI' s 10-Year ROE (%) Range
Min: -2624.11   Max: 33.19
Current: 33.19

-2624.11
33.19
ROA (%) 18.67
SPPI's ROA (%) is ranked higher than
75% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -17.51 vs. SPPI: 18.67 )
SPPI' s 10-Year ROA (%) Range
Min: -510.69   Max: 18.67
Current: 18.67

-510.69
18.67
ROC (Joel Greenblatt) (%) 3132.81
SPPI's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 876 Companies
in the Global Biotechnology industry.

( Industry Median: -201.33 vs. SPPI: 3132.81 )
SPPI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5194.83   Max: 3132.81
Current: 3132.81

-5194.83
3132.81
Revenue Growth (%) 62.20
SPPI's Revenue Growth (%) is ranked higher than
90% of the 638 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. SPPI: 62.20 )
SPPI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 211.9
Current: 62.2

0
211.9
» SPPI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

SPPI Guru Trades in Q3 2013

Jim Simons 12,017 sh (New)
» More
Q4 2013

SPPI Guru Trades in Q4 2013

Paul Tudor Jones 13,000 sh (New)
Jim Simons 69,517 sh (+478.49%)
» More
Q1 2014

SPPI Guru Trades in Q1 2014

Jim Simons 171,307 sh (+146.42%)
Paul Tudor Jones Sold Out
» More
Q2 2014

SPPI Guru Trades in Q2 2014

Jim Simons 185,917 sh (+8.53%)
» More
» Details

Insider Trades

Latest Guru Trades with SPPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2012-12-31 Sold Out 0.13%$10.64 - $12.31 $ 7.91-31%0
Joel Greenblatt 2012-12-31 Sold Out 0.02%$10.64 - $12.31 $ 7.91-31%0
Joel Greenblatt 2012-12-31 Sold Out 0.02%$10.64 - $12.31 $ 7.91-31%0
John Burbank 2012-09-30 New Buy0.13%$11.6 - $17.05 $ 7.91-43%250000
Joel Greenblatt 2012-09-30 New Buy0.02%$11.6 - $17.05 $ 7.91-43%19901
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.94
SPPI's P/B is ranked higher than
87% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. SPPI: 1.94 )
SPPI' s 10-Year P/B Range
Min: 0.54   Max: 5.23
Current: 1.94

0.54
5.23
P/S 3.11
SPPI's P/S is ranked higher than
86% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 17.18 vs. SPPI: 3.11 )
SPPI' s 10-Year P/S Range
Min: 1.07   Max: 367
Current: 3.11

1.07
367
EV-to-EBIT -8.65
SPPI's EV-to-EBIT is ranked higher than
60% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SPPI: -8.65 )
SPPI' s 10-Year EV-to-EBIT Range
Min: 5.6   Max: 63.5
Current: -8.65

5.6
63.5
Current Ratio 2.72
SPPI's Current Ratio is ranked higher than
66% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. SPPI: 2.72 )
SPPI' s 10-Year Current Ratio Range
Min: 0.56   Max: 16.82
Current: 2.72

0.56
16.82
Quick Ratio 2.55
SPPI's Quick Ratio is ranked higher than
68% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. SPPI: 2.55 )
SPPI' s 10-Year Quick Ratio Range
Min: 0.56   Max: 16.8
Current: 2.55

0.56
16.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 23.97
SPPI's Price/Tangible Book is ranked lower than
59% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 8.60 vs. SPPI: 23.97 )
SPPI' s 10-Year Price/Tangible Book Range
Min: 0.66   Max: 190.1
Current: 23.97

0.66
190.1
Price/DCF (Projected) 2.00
SPPI's Price/DCF (Projected) is ranked higher than
94% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SPPI: 2.00 )
SPPI' s 10-Year Price/DCF (Projected) Range
Min: 1.34   Max: 12.51
Current: 2

1.34
12.51
Price/Median PS Value 0.66
SPPI's Price/Median PS Value is ranked higher than
88% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. SPPI: 0.66 )
SPPI' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 1970
Current: 0.66

0.12
1970
Earnings Yield (Greenblatt) 3.40
SPPI's Earnings Yield (Greenblatt) is ranked higher than
54% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. SPPI: 3.40 )
SPPI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 17.7
Current: 3.4

1.6
17.7
Forward Rate of Return (Yacktman) 0.25
SPPI's Forward Rate of Return (Yacktman) is ranked higher than
89% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. SPPI: 0.25 )
SPPI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9.6   Max: -1.1
Current: 0.25

-9.6
-1.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NTR.Germany
Spectrum Pharmaceuticals Inc is a Delaware corporation that was originally incorporated in Colorado as Americus Funding Corporation in December 1987, became NeoTherapeutics, Inc. in August 1996, was reincorporated in Delaware in June 1997, and was renamed Spectrum Pharmaceuticals, Inc. in December 2002. The Company is a biotechnology company integrated with commercial and drug development operations primarily in hematology and oncology. It markets three oncology drugs, FUSILEV , FOLOTYN and ZEVALIN and also market ZEVALIN outside of the U.S. The Company has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of novel drug candidates. The Company has assembled an integrated in-house scientific team, including formulation development, clinical development, medical affairs, regulatory affairs, biostatistics and data management, and has established a commercial infrastructure for the marketing of its drug products. The Company product portfolio is consist of both commercial stage and development stage products. The Company's products are manufactured on a contract basis. It has built and develop, a sales and marketing infrastructure as part of its commercialization efforts for FUSILEV, ZEVALIN and FOLOTYN. The Company have limited number of customers which include Oncology Supply, McKesson Specialty, ICS and Cardinal Health. The Company competes with Abraxis Bioscience, Inc., Astra Zeneca LP, Bayer AG, Endo Pharmaceuticals, Eli Lilly and Co., Novartis Pharmaceuticals, Corporation, Genentech, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, Biogen-IDEC Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc., Cephalon, Inc., Sanofi-Aventis, Inc., Pfizer, Inc., Genta Incorporated, Merck, Celgene Corporation, BiPar Sciences, Inc., Genzyme Corporation, Shire Pharmaceuticals, Abbott Laboratories, Poniard Pharmaceuticals, Inc., Roche Pharmaceuticals and Johnson & Johnson. The development, production and marketing of the company's proprietary and generic drug and biologic products are subject to regulation for safety, efficacy and quality by numerous governmental authorities in the U.S. and other countries.
» More Articles for SPPI

Headlines

Articles On GuruFocus.com
http://seekingalpha. Aug 14 2012 
Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 
5 Stocks Exceeding Expectations In 2012 Mar 31 2012 
Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Weekly CFO Buys Highlight: CNYD, PRWT, ANCB, SPPI, SPAX Jan 30 2011 
Weekly CFO Buys Highlight: FUL, SPPI, GRF, BPAX Jan 24 2011 
Weekly Top Insider Buys: NPBC, FUL, GAM, SHLM, SPPI Jan 23 2011 
Spectrum Pharmaceuticals Inc. (SPPI) CFO Brett L Scott buys 4,000 Shares Jan 21 2011 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
Why Spectrum Fell on Beleodaq Approval but Will Rocket on Melphalan Approval Aug 18 2014
SPECTRUM PHARMACEUTICALS INC Financials Aug 15 2014
Spectrum Pharmaceuticals (SPPI) Posts Strong Earnings in Q2 Aug 12 2014
SPECTRUM PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 08 2014
H.C. Wainwright & Co. Sees Significant Upside Ahead For Spectrum Pharmaceuticals Aug 08 2014
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 07 2014
Spectrum Pharmaceuticals Reports 45% Sales Growth in the Second Quarter, Launches Fifth Product and... Aug 07 2014
Spectrum Pharmaceuticals Reports 45% Sales Growth in the Second Quarter, Launches Fifth Product and... Aug 07 2014
Q2 2014 Spectrum Pharmaceuticals Inc Earnings Release - After Market Close Aug 07 2014
Spectrum Pharmaceuticals Announces Second Quarter 2014 Financial Results Teleconference and Webcast Jul 31 2014
Spectrum Pharmaceuticals Announces Second Quarter 2014 Financial Results Teleconference and Webcast Jul 31 2014
Spectrum Pharma upgraded by R. F. Lafferty Jul 15 2014
Spectrum Pharmaceuticals: Key Drug Fusilev May Face Generic Competition Soon Jul 09 2014
Spectrum Pharmaceuticals Gains U.S. Approval of Beleodaq Jul 07 2014
Spectrum receives accelerated FDA approval for Beleodaq Jul 07 2014
Why Spectrum Pharmaceuticals (SPPI) Stock Is Higher This Morning Jul 07 2014
FDA Grants Spectrum Pharmaceuticals Accelerated Approval of Beleodaq™ (belinostat) for Injection Jul 07 2014
Spectrum Pharmaceuticals granted accelerated approval of lymphoma treatment Jul 07 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide